Athira Pharma Inc. (ATHR) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases such as Alzheimer's. This report evaluates its Shariah compliance through financial screening, business activity analysis, ESG factors, and index inclusion status. The core business is permissible, with low debt and liquidity ratios, but the interest income ratio of 8.42% exceeds the 5% threshold, leading to exclusion from major Shariah indices. Regional variations exist, with compliance in Malaysia and Indonesia but non-compliance under AAOIFI and GCC standards. Investors should consider purification and monitor financial evolution for potential future compliance.